Sushith Sushith1, Herijenahalli Nagaraju Krishnamurthy1, Shridhar Reshma1, D'Sa Janice1, Gopal Madan1, Kumar Jeppu Ashok1,2, Mangalore Balakrishna Prathima1, Bhuvanesh Sukhlal Kalal3,4. 1. Department of Biochemistry, A. J. Institute of Medical Sciences and Research Centre, Mangaluru 575004, Karnataka, India. 2. International Medical School, Management and Science University, Shah Alam, Selangor 40100, Malaysia. 3. A. J. Research Centre, A. J. Institute of Medical Sciences and Research Centre, Mangaluru 575004, Karnataka, India. 4. Ophthalmology, Visual & Anatomical Sciences, Wayne State University, Kresge Eye Institute, Detroit, Michigan 48201, United States of America.
Abstract
BACKGROUND: The objective of this study was to determine the levels of serum ischemia-modified albumin (IMA), fibrinogen (FIB) and high sensitivity C-reactive protein (hs-CRP) in type 2 diabetes mellitus (T2DM) patients with hypertension (HT) (DMT2HTN) and without HT (DMT2). Also, their association with certain biochemical and physical factors were studied to identify possible risk factors that lead to cardiovascular complications. METHODS: Fasting blood samples were collected from 35 DMT2 or DMT2HTN patients each to analyze differences in serum and plasma levels of IMA, hs-CRP, FIB, total cholesterol (TC), high and low density lipoproteins (HDL and LDL), triglyceride (TG), hemoglobin A1c (HbA1C), glycated hemoglobin and creatinine. RESULTS: In DMT2 and DMT2HTN patients, IMA, hs-CRP, FIB, TC, TG, HDL, LDL, glycated hemoglobin and creatinine levels, including body mass index (BMI) and waist-to-hip ratio (WHR), were significantly higher relative to healthy controls. In addition, the levels of IMA, hs-CRP and FIB levels showed a strong link to BMI, WHR, TC, TG, LDL and glycated hemoglobin. Lastly, both DMT2 and DMT2HTN patients demonstrated a significant reduction in HDL. CONCLUSION: DMT2 and DMT2HTN patients have a greater risk of developing cardiovascular related complications. This study suggests that quantifying hs-CRP, IMA and FIB levels can help diagnose the risk of developing complications during the early stages of metabolic and cardiovascular disease. Overall, the specific risk factors may be used for early identification of cardiovascular complications to decrease mortality and morbidity in T2DM patients.
BACKGROUND: The objective of this study was to determine the levels of serum ischemia-modified albumin (IMA), fibrinogen (FIB) and high sensitivity C-reactive protein (hs-CRP) in type 2 diabetes mellitus (T2DM) patients with hypertension (HT) (DMT2HTN) and without HT (DMT2). Also, their association with certain biochemical and physical factors were studied to identify possible risk factors that lead to cardiovascular complications. METHODS: Fasting blood samples were collected from 35 DMT2 or DMT2HTN patients each to analyze differences in serum and plasma levels of IMA, hs-CRP, FIB, total cholesterol (TC), high and low density lipoproteins (HDL and LDL), triglyceride (TG), hemoglobin A1c (HbA1C), glycated hemoglobin and creatinine. RESULTS: In DMT2 and DMT2HTN patients, IMA, hs-CRP, FIB, TC, TG, HDL, LDL, glycated hemoglobin and creatinine levels, including body mass index (BMI) and waist-to-hip ratio (WHR), were significantly higher relative to healthy controls. In addition, the levels of IMA, hs-CRP and FIB levels showed a strong link to BMI, WHR, TC, TG, LDL and glycated hemoglobin. Lastly, both DMT2 and DMT2HTN patients demonstrated a significant reduction in HDL. CONCLUSION: DMT2 and DMT2HTN patients have a greater risk of developing cardiovascular related complications. This study suggests that quantifying hs-CRP, IMA and FIB levels can help diagnose the risk of developing complications during the early stages of metabolic and cardiovascular disease. Overall, the specific risk factors may be used for early identification of cardiovascular complications to decrease mortality and morbidity in T2DM patients.
Entities:
Keywords:
Diabetes Mellitus; Fibrinogen; Hemoglobin; High sensitivity C reactive proteins; Hypertension; Ischemia modified albumin
Authors: Ian H de Boer; Sripal Bangalore; Athanase Benetos; Andrew M Davis; Erin D Michos; Paul Muntner; Peter Rossing; Sophia Zoungas; George Bakris Journal: Diabetes Care Date: 2017-09 Impact factor: 19.112
Authors: Maria do Rosário Gondim Peixoto; Maria Helena D'Aquino Benício; Maria do Rosário Dias de Oliveira Latorre; Paulo César Brandão Veiga Jardim Journal: Arq Bras Cardiol Date: 2006-10 Impact factor: 2.000
Authors: Kubilay Ukinc; Selcuk Eminagaoglu; Halil Onder Ersoz; Cihangir Erem; Caner Karahan; Arif Bayram Hacihasanoglu; Mustafa Kocak Journal: Endocrine Date: 2009-09-26 Impact factor: 3.633